Close Menu

NEW YORK (GenomeWeb) – Pathology Associates Medical Laboratories (PAML) today announced that it has entered into a collaboration with Axela to develop multiplex assays to detect patient immunity to diseases that can be prevented with vaccines.

The serologic assays will measure antibodies to a wide range of viruses including measles, mumps, and rubella to help determine a patient's immunity to those diseases. The terms of the agreement also call for multiplex targets beyond the initial serological assays.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.